top of page

NCI-2022-07859

OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy


This research study is looking at whether a treatment with pembrolizumab is necessary after surgery for patients with early-stage triple-negative breast cancer (TNBC). The trial is designed for patients with early-stage TNBC who achieved pathologic complete response (pCR) after neoadjuvant chemotherapy that also included pembrolizumab. Traditionally, after achieving pCR, patients would receive additional pembrolizumab. This trial is looking to see if skipping this additional pembrolizumab after surgery leads to the same outcome for patients as receiving it.


Triple-Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.


For more information about the trial, click the link below:

NCI-2022-07859

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2019-07694

Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2) This is a research study called NAPOLI-2. It is designed to see

NCT05908786

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CAR

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatoce

Comments


bottom of page